Medicare drug coverage faces an ominous spending outlook
Summary
New data shows that Medicare drug spending is increasing faster than expected, mainly due to higher use of expensive drugs and patients reaching their cost limits. This growing cost could strain Medicare’s budget and may lead to higher expenses for seniors or cuts in benefits in the future.Key Facts
- The Inflation Reduction Act (IRA) lowered out-of-pocket costs for seniors on outpatient prescription drugs, shifting costs to taxpayers, insurers, and drug makers.
- In 2025, over 20% of Medicare Part D enrollees hit the $2,000 patient cost cap, moving extra costs to the government and insurers.
- Spending on GLP-1 weight-loss drugs grew from $300 million in 2024 to $2 billion last year, contributing to cost increases.
- Cancer and diabetes drugs also showed significant spending growth.
- Medicare drug spending is expected to grow faster than the overall economy and could make up 44% of the federal deficit from drugs, doctor visits, and outpatient services over the next decade.
- Some cost-control tools are limited, causing concerns about long-term financial sustainability.
- Several cost-limiting programs and subsidies are set to expire soon, which may raise costs for seniors.
- Medicare drug prices negotiations and use of cheaper generic drugs are helping but are not enough to fully offset spending growth.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
